PIK3CA Solid Tumors clinical trials
9 active Solid Tumors trials that test for PIK3CA in their eligibility criteria. Describe your situation to see which ones look like a fit.
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- SNV4818 in Participants With Advanced Solid Tumors
- A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
- Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.